Science News
from research organizations

Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival

Date:
November 23, 2015
Source:
European Organisation for Research and Treatment of Cancer
Summary:
Bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage, report scientists.
Share:
FULL STORY

Results of EORTC trial 26101 presented at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage.

Prof. Dr. Wolfgang Wick of the Uniklinik Heidelberg and coordinator of this study says, "The future challenge is to identify those patients deriving benefit from that treatment."

With an annual incidence of approximately five cases per 100,000 persons, gliomas are the most frequently occurring brain tumor in adults. Glioblastomas represent roughly 60-70% of all gliomas, and for this type of glioma there is no curative treatment.

"Standard first line treatment consists of surgical resection followed by radiation and concomitant and adjuvant temozolomide therapy. For recurrence, there are treatment options, but we still have no standard treatment," points out Dr. Wick. "Phase II data from the BELOB trial had indicated that the combination of bevacizumab and lomustine might produce an overall survival benefit compared with either monotherapy for patients with first progression of a glioblastoma."


Story Source:

Materials provided by European Organisation for Research and Treatment of Cancer. Original written by John Bean. Note: Content may be edited for style and length.


Cite This Page:

European Organisation for Research and Treatment of Cancer. "Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival." ScienceDaily. ScienceDaily, 23 November 2015. <www.sciencedaily.com/releases/2015/11/151123101857.htm>.
European Organisation for Research and Treatment of Cancer. (2015, November 23). Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival. ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2015/11/151123101857.htm
European Organisation for Research and Treatment of Cancer. "Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs progression-free survival, but not overall survival." ScienceDaily. www.sciencedaily.com/releases/2015/11/151123101857.htm (accessed May 26, 2017).

RELATED STORIES